Rami Wajih Nasr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rami Wajih Nasr has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Nassib Abou Heidar
Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
9 shared publications - Jad Ahmad Degheili
Univ Ottawa, Childrens Hosp Eastern Ontario, Div Pediat Urol, Dept Surg, Ottawa, ON, Canada
4 shared publications - Albert El Hajj
American University of Beirut Medical Center
3 shared publications Jana H. Mahdi
Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon
3 shared publications- Maya T. Herrera
Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon
3 shared publications - Muhammad Bulbul
American University of Beirut Medical Center
3 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in BMC Urology
- Vol. 26 (1)
Trends in rates and outcomes of benign prostatic hyperplasia surgeries: a retrospective cohort study using the ACS-NSQIP database (2008–2021)
Advancements in surgical techniques have led to a shift in the types of procedures performed for BPH. This study aims to analyze trends in rates and outcomes of surgical procedures for BPH between 2008 and 2021. Using the ACS-NSQIP database, patients who underwent BPH surgery between 2008 and 2021 were identified. Trends, baseline characteristics and perioperative outcomes were collected for transurethral resection of prostate (TURP), photo-vaporization of prostate (PVP), Laser enucleation of the prostate (LEP) and simple prostatectomy. A total of 99,291 BPH procedures were recorded, increasing from 850 in 2008 to 11,005 in 2021. TURP was the most performed procedure with rates rising from 56.1% in 2008 to 65.2% in 2021. PVP was the second most performed procedure, with rates decreasing from 41.6% in 2008 to 22.5% in 2021. LEP procedures were not recorded prior to 2011 after which the number increased from 82 (2.6%) procedures in 2011 to 971 (8.8%) in 2021. Simple prostatectomy had a relatively stable rate over the course of 14 years (1.8%-3.4%). Over time, a reduction in hospital stay (1.3 to 1.1 days, p < 0.001), and an increase in operative time were observed (55 min ± 31.81 to 66 min ± 46.6, p < 0.001). There has been a noticeable shift in the surgical management of BPH between 2008 and 2021, with a clear trend favoring novel techniques. Utilizing these approaches has led to improvements in perioperative outcomes. Further research is necessary to evaluate long-term outcomes and cost-effectiveness of novel techniques.
- 14 July 2026
- Published by Springer Nature in BMC Urology
- Vol. 26 (1)
Open AccessTrends in rates and outcomes of benign prostatic hyperplasia surgeries: a retrospective cohort study using the ACS-NSQIP database (2008–2021)
Advancements in surgical techniques have led to a shift in the types of procedures performed for BPH. This study aims to analyze trends in rates and outcomes of surgical procedures for BPH between 2008 and 2021. Using the ACS-NSQIP database, patients who underwent BPH surgery between 2008 and 2021 were identified. Trends, baseline characteristics and perioperative outcomes were collected for transurethral resection of prostate (TURP), photo-vaporization of prostate (PVP), Laser enucleation of the prostate (LEP) and simple prostatectomy. A total of 99,291 BPH procedures were recorded, increasing from 850 in 2008 to 11,005 in 2021. TURP was the most performed procedure with rates rising from 56.1% in 2008 to 65.2% in 2021. PVP was the second most performed procedure, with rates decreasing from 41.6% in 2008 to 22.5% in 2021. LEP procedures were not recorded prior to 2011 after which the number increased from 82 (2.6%) procedures in 2011 to 971 (8.8%) in 2021. Simple prostatectomy had a relatively stable rate over the course of 14 years (1.8%-3.4%). Over time, a reduction in hospital stay (1.3 to 1.1 days, p < 0.001), and an increase in operative time were observed (55 min ± 31.81 to 66 min ± 46.6, p < 0.001). There has been a noticeable shift in the surgical management of BPH between 2008 and 2021, with a clear trend favoring novel techniques. Utilizing these approaches has led to improvements in perioperative outcomes. Further research is necessary to evaluate long-term outcomes and cost-effectiveness of novel techniques.
- 25 August 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (30) , 3873-3884
Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01)
Muscle-invasive bladder cancer (MIBC) has a 5-year survival rate of 40-60% following traditional treatment with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), which significantly impacts quality of life. Bladder preservation strategies, including maximal transurethral resection of the bladder tumor (TURBT), NAC, and radiation therapy, offer similar survival rates with better quality of life. Immune checkpoint inhibitors like avelumab show potential benefits when combined with bladder preservation modalities. This phase II randomized, non-comparative, double-arm, open-label, multicenter trial evaluates the efficacy and safety of two tetra-modality bladder preservation strategies in MIBC patients (T2-T4N0M0). The primary endpoint is the 2-year proportion of bladder-preserved participants. Secondary endpoints include response rates post-induction, quality of life, and safety evaluations. Eighty participants will be randomized 1:1 into Arm A or Arm B. All participants will first receive induction chemotherapy (DDMVAC or GC) combined with avelumab, followed by disease evaluation using imaging and TURBT. Those achieving a complete or near-complete response will proceed to hypofractionated radiation therapy (55 Grays in 20 fractions). After radiation, Arm A will receive maintenance avelumab for 1 year, while Arm B will follow a watch-and-wait approach. Non-responders in both arms will be referred for salvage RC. NCT06686381 (ClinicalTrials.gov).
- 25 August 2025
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (30) , 3873-3884
Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01)
Muscle-invasive bladder cancer (MIBC) has a 5-year survival rate of 40-60% following traditional treatment with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), which significantly impacts quality of life. Bladder preservation strategies, including maximal transurethral resection of the bladder tumor (TURBT), NAC, and radiation therapy, offer similar survival rates with better quality of life. Immune checkpoint inhibitors like avelumab show potential benefits when combined with bladder preservation modalities. This phase II randomized, non-comparative, double-arm, open-label, multicenter trial evaluates the efficacy and safety of two tetra-modality bladder preservation strategies in MIBC patients (T2-T4N0M0). The primary endpoint is the 2-year proportion of bladder-preserved participants. Secondary endpoints include response rates post-induction, quality of life, and safety evaluations. Eighty participants will be randomized 1:1 into Arm A or Arm B. All participants will first receive induction chemotherapy (DDMVAC or GC) combined with avelumab, followed by disease evaluation using imaging and TURBT. Those achieving a complete or near-complete response will proceed to hypofractionated radiation therapy (55 Grays in 20 fractions). After radiation, Arm A will receive maintenance avelumab for 1 year, while Arm B will follow a watch-and-wait approach. Non-responders in both arms will be referred for salvage RC. NCT06686381 (ClinicalTrials.gov).
- Open Access
- 27 May 2025
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 24 (1) , 57-65
Infection rates of trans-perineal versus trans-rectal prostate biopsy: A Middle Eastern tertiary center experience—Time for a change?
Prostate cancer is the most diagnosed cancer in men, with transrectal ultrasound-guided (TRUS) biopsy being the most frequently used method of tissue diagnosis in the past. With the introduction of the new modality of trans-perineal (TP) ultrasound-guided prostate biopsy, urologists and radiologists adopted this new technique for the decreased rate of complications such as urinary tract infections, bacteremia, sepsis and the avoidance of antimicrobial prophylaxis. We aim to compare the infectious rates of TRUS versus TP biopsy from our Middle Eastern tertiary care center. Retrospective data was collected on patients from our medical records from May 2019 till December 2023 at our institution. The data included adult male patients aged 18 years and above undergoing TP or TRUS prostate biopsy. Patients with positive urine culture before biopsy were excluded. Electronic medical records, pathology and laboratory reports were reviewed to collect patient-related data including age, BMI, smoking, alcohol consumption, medical history and comorbidities. In addition, variables related to the procedure type, the target lesion location, antibiotic prophylaxis, bowl preparation, number of cores taken, and laterality of the tumor were included. A total of 745 patients underwent an ultrasound guided prostate biopsy performed by 6 attending urologists at our institution. Among them, 157 (21.1%) patients underwent TRUS biopsy, while 588 (78.9%) underwent TP biopsy. Within one month of the biopsy, 13 patients (1.7%) developed UTI. 6 of them had TRUS (4.1%), and 7 had TP (1.2%) with p = 0.03. Four patients required hospital admission for fever and bacteremia, all of which had undergone TRUS biopsy with hospital stay from 2–5 days receiving meropenem, ciprofloxacin, cefixime or Bactrim. TP prostate biopsy carries a lower risk of infectious complications and requires no antibiotic prophylaxis compared to TRUS biopsy of the prostate. These results advocate the superiority of the use of TP biopsy over TRUS biopsy.
- 27 May 2025
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 24 (1) , 57-65
Open AccessInfection rates of trans-perineal versus trans-rectal prostate biopsy: A Middle Eastern tertiary center experience—Time for a change?
Prostate cancer is the most diagnosed cancer in men, with transrectal ultrasound-guided (TRUS) biopsy being the most frequently used method of tissue diagnosis in the past. With the introduction of the new modality of trans-perineal (TP) ultrasound-guided prostate biopsy, urologists and radiologists adopted this new technique for the decreased rate of complications such as urinary tract infections, bacteremia, sepsis and the avoidance of antimicrobial prophylaxis. We aim to compare the infectious rates of TRUS versus TP biopsy from our Middle Eastern tertiary care center. Retrospective data was collected on patients from our medical records from May 2019 till December 2023 at our institution. The data included adult male patients aged 18 years and above undergoing TP or TRUS prostate biopsy. Patients with positive urine culture before biopsy were excluded. Electronic medical records, pathology and laboratory reports were reviewed to collect patient-related data including age, BMI, smoking, alcohol consumption, medical history and comorbidities. In addition, variables related to the procedure type, the target lesion location, antibiotic prophylaxis, bowl preparation, number of cores taken, and laterality of the tumor were included. A total of 745 patients underwent an ultrasound guided prostate biopsy performed by 6 attending urologists at our institution. Among them, 157 (21.1%) patients underwent TRUS biopsy, while 588 (78.9%) underwent TP biopsy. Within one month of the biopsy, 13 patients (1.7%) developed UTI. 6 of them had TRUS (4.1%), and 7 had TP (1.2%) with p = 0.03. Four patients required hospital admission for fever and bacteremia, all of which had undergone TRUS biopsy with hospital stay from 2–5 days receiving meropenem, ciprofloxacin, cefixime or Bactrim. TP prostate biopsy carries a lower risk of infectious complications and requires no antibiotic prophylaxis compared to TRUS biopsy of the prostate. These results advocate the superiority of the use of TP biopsy over TRUS biopsy.
- 15 January 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
The impact of kidney disease on peri-operative outcomes of novel BPH surgeries across the board: a propensity score matched analysis using the ACS-NSQIP database
Background Pre-operative kidney disease was shown to impact peri-operative outcomes of endoscopic BPH surgeries. We aim to assess the effect of novel surgical techniques (Laser Enucleation of the Prostate (LEP) and Laser Vaporization of the Prostate (LVP)) compared to Transurethral Resection of Prostate (TURP), on post-operative outcomes stratified based on kidney function. Methods The ACS-NSQIP database was reviewed from 2008 to 2021 for 83,020 patients that underwent TURP, LEP, and LVP. Pre-operative variables were compared across kidney function groups: G1(normal/high function); G2-G3(mild/moderate kidney disease); and G4-G5(severe kidney disease). Multivariate logistic regression was performed on 30-day peri-operative complications adjusting for pre-operative variables. Propensity score matching was done between LEP and LVP to TURP. Results LEP showed a protective effect against UTIs (p < 0.05) in the G1 and G2-G3 categories but lost that protective effect in the G4-G5 category when compared to TURP. It had longer operative time (p < 0.05) across all kidney function groups, and demonstrated shorter hospital stay (p < 0.05) in the G1 and G2-G3 categories compared to TURP. LVP had a persistent protective effect against bleeding (p < 0.05) across all kidney function groups and shorter hospital stay (p < 0.05) when compared to TURP. LVP had a protective effect against return to OR (p < 0.05) in the G1 and G2-G3 kidney function group but lost that protective effect in the G4-G5 category. LVP had significant protective effect against thromboembolic events (p < 0.05) in the G2-G3 category and against cardiac complications (p < 0.05) in the G4-G5 category. Conclusion LEP and LVP are superior to TURP in terms of post-operative complications. The type of endoscopic surgery technique should be tailored according to patient’s pre-operative kidney status and risk.
- 15 January 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
The impact of kidney disease on peri-operative outcomes of novel BPH surgeries across the board: a propensity score matched analysis using the ACS-NSQIP database
Background Pre-operative kidney disease was shown to impact peri-operative outcomes of endoscopic BPH surgeries. We aim to assess the effect of novel surgical techniques (Laser Enucleation of the Prostate (LEP) and Laser Vaporization of the Prostate (LVP)) compared to Transurethral Resection of Prostate (TURP), on post-operative outcomes stratified based on kidney function. Methods The ACS-NSQIP database was reviewed from 2008 to 2021 for 83,020 patients that underwent TURP, LEP, and LVP. Pre-operative variables were compared across kidney function groups: G1(normal/high function); G2-G3(mild/moderate kidney disease); and G4-G5(severe kidney disease). Multivariate logistic regression was performed on 30-day peri-operative complications adjusting for pre-operative variables. Propensity score matching was done between LEP and LVP to TURP. Results LEP showed a protective effect against UTIs (p < 0.05) in the G1 and G2-G3 categories but lost that protective effect in the G4-G5 category when compared to TURP. It had longer operative time (p < 0.05) across all kidney function groups, and demonstrated shorter hospital stay (p < 0.05) in the G1 and G2-G3 categories compared to TURP. LVP had a persistent protective effect against bleeding (p < 0.05) across all kidney function groups and shorter hospital stay (p < 0.05) when compared to TURP. LVP had a protective effect against return to OR (p < 0.05) in the G1 and G2-G3 kidney function group but lost that protective effect in the G4-G5 category. LVP had significant protective effect against thromboembolic events (p < 0.05) in the G2-G3 category and against cardiac complications (p < 0.05) in the G4-G5 category. Conclusion LEP and LVP are superior to TURP in terms of post-operative complications. The type of endoscopic surgery technique should be tailored according to patient’s pre-operative kidney status and risk.
- Open Access
- 1 September 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 122 (C) , 110078
Peno-scrotal metastasis of colorectal adenocarcinoma: A case report and review of the literature
Introduction: Colorectal cancer is the second most common cause of death worldwide and may present as metastatic disease involving the liver, lungs and bones, and pelvic organs. Penile and scrotal metastasis may occur secondary to primary tumors originating from the genito-urinary tract. Case presentation: We present a case of rectal adenocarcinoma metastatic to the penis and scrotum s/p chemotherapy and radiotherapy. His metastatic involvement was complicated by infections, necrosis and growth of maggots. Patient underwent wide excision and debridement of the metastatic deposits in the pubic, penile, scrotal and perineal region in addition to split-tissue skin graft from the right anterior thigh to cover the pubic region, the remainder of the penile shaft, and the scrotum. Clinical discussion: Peno-scrotal metastasis secondary to rectal adenocarcinoma is a rare condition. It may present as malignant priapism, hematuria, obstructive urinary symptoms occurring when there is urethral involvement. The mechanism of metastasis may be due to retrograde venous flow from the vesical, pudendal, hemorrhoidal plexuses, and the prostatic venous plexus draining the cavernosal veins of the penis. Additionally, lymphatic involvement and spread may play an important role in the spread of the disease. Treatment of such conditions relies on chemotherapy and radiotherapy and surgery for local control and symptomatic treatment. Conclusion: This article describes the rare occurrence of peno-scrotal metastasis of rectal adenocarcinoma and provides an overview on diagnosis, etiology, and management of the disease. Highlights:
- 1 September 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 122 (C) , 110078
Open AccessPeno-scrotal metastasis of colorectal adenocarcinoma: A case report and review of the literature
Introduction: Colorectal cancer is the second most common cause of death worldwide and may present as metastatic disease involving the liver, lungs and bones, and pelvic organs. Penile and scrotal metastasis may occur secondary to primary tumors originating from the genito-urinary tract. Case presentation: We present a case of rectal adenocarcinoma metastatic to the penis and scrotum s/p chemotherapy and radiotherapy. His metastatic involvement was complicated by infections, necrosis and growth of maggots. Patient underwent wide excision and debridement of the metastatic deposits in the pubic, penile, scrotal and perineal region in addition to split-tissue skin graft from the right anterior thigh to cover the pubic region, the remainder of the penile shaft, and the scrotum. Clinical discussion: Peno-scrotal metastasis secondary to rectal adenocarcinoma is a rare condition. It may present as malignant priapism, hematuria, obstructive urinary symptoms occurring when there is urethral involvement. The mechanism of metastasis may be due to retrograde venous flow from the vesical, pudendal, hemorrhoidal plexuses, and the prostatic venous plexus draining the cavernosal veins of the penis. Additionally, lymphatic involvement and spread may play an important role in the spread of the disease. Treatment of such conditions relies on chemotherapy and radiotherapy and surgery for local control and symptomatic treatment. Conclusion: This article describes the rare occurrence of peno-scrotal metastasis of rectal adenocarcinoma and provides an overview on diagnosis, etiology, and management of the disease. Highlights:
- 19 May 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-7
Impact of kidney disease on perioperative outcomes of endoscopic BPH surgery: a propensity score matched analysis from the NSQIP database
Introduction To assess the impact of kidney function in patients with BPH undergoing surgery prior to Transurethral resection of prostate (TURP), Laser enucleation of the prostate (LEP), and Laser Vaporization of the prostate (LVP) on operative and post-operative outcomes using the ACS-NSQIP database. Methods The ACS-NSQIP database was reviewed for patients that underwent TURP, LEP and LVP for treatment of patients with BPH between the years of 2008 and 2021. Demographics, comorbidities, bleeding disorders, operative time, and surgical procedure performed were collected for comparison between Kidney function groups: G1, normal/high function; G2-G3, mild/moderate kidney disease; and G4-G5, severe kidney disease. The 30-day peri-operative complications were measured and a multivariate logistic regression analysis was performed while adjusting for all confounding variables. Propensity score matching was performed between the G1 and G4-G5 cohorts. Results A total of 83,020 patients were included. On multivariable regression, in the G2-G3 cohort, patients were at significantly increased risk for renal complications with OR = 2.43[1.56–3.79]. After propensity score matching, the G4-G5 cohort showed increased odds of pneumonia OR = 4.02[1.343–12.056], renal complications with OR = 7.62[2.283–25.411], cardiac complications OR = 4.53[1.531–13.411], and sepsis/septic shock OR = 1.76[1.091–2.834]. They also had a higher need for blood transfusion OR = 3.58[2.242–5.714], and prolonged hospital stay with OR = 1.49[1.296–1.723]. Conclusion Pre-operative kidney disease may pose an increased risk of complications for patients undergoing endoscopic BPH surgery. The literature lacks information on the effect of pre-operative kidney disease on endoscopic BPH surgeries. Further studies are required to compare post-operative outcomes of LEP and LVP as compared to TURP across kidney function status.
- 19 May 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-7
Impact of kidney disease on perioperative outcomes of endoscopic BPH surgery: a propensity score matched analysis from the NSQIP database
Introduction To assess the impact of kidney function in patients with BPH undergoing surgery prior to Transurethral resection of prostate (TURP), Laser enucleation of the prostate (LEP), and Laser Vaporization of the prostate (LVP) on operative and post-operative outcomes using the ACS-NSQIP database. Methods The ACS-NSQIP database was reviewed for patients that underwent TURP, LEP and LVP for treatment of patients with BPH between the years of 2008 and 2021. Demographics, comorbidities, bleeding disorders, operative time, and surgical procedure performed were collected for comparison between Kidney function groups: G1, normal/high function; G2-G3, mild/moderate kidney disease; and G4-G5, severe kidney disease. The 30-day peri-operative complications were measured and a multivariate logistic regression analysis was performed while adjusting for all confounding variables. Propensity score matching was performed between the G1 and G4-G5 cohorts. Results A total of 83,020 patients were included. On multivariable regression, in the G2-G3 cohort, patients were at significantly increased risk for renal complications with OR = 2.43[1.56–3.79]. After propensity score matching, the G4-G5 cohort showed increased odds of pneumonia OR = 4.02[1.343–12.056], renal complications with OR = 7.62[2.283–25.411], cardiac complications OR = 4.53[1.531–13.411], and sepsis/septic shock OR = 1.76[1.091–2.834]. They also had a higher need for blood transfusion OR = 3.58[2.242–5.714], and prolonged hospital stay with OR = 1.49[1.296–1.723]. Conclusion Pre-operative kidney disease may pose an increased risk of complications for patients undergoing endoscopic BPH surgery. The literature lacks information on the effect of pre-operative kidney disease on endoscopic BPH surgeries. Further studies are required to compare post-operative outcomes of LEP and LVP as compared to TURP across kidney function status.
- Open Access
- 1 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 118 (C) , 109625
Gastric Outlet Obstruction as a presentation of Metastatic Squamous Cell Carcinoma of the Bladder: A case report and review of the literature
Introduction: Gastric outlet obstruction presents with a range of symptoms which include abdominal pain, early satiety, weight loss and vomiting caused obstruction secondary to tumors from outside the gastrointestinal tract or due to motility disorders. Bladder cancer is rarely associated with Gastric outlet obstruction. It usually presents with painless hematuria and urinary symptoms. Squamous cell carcinoma is a subtype of bladder malignancies that tends to present at a later stage and is associated with poorer prognosis in terms of metastasis and survival. Case presentation: We present the case of a 79-year-old man, non-smoker, who presented to the emergency department with gastric outlet obstruction and was found to have non-bilharzial squamous cell carcinoma of the bladder metastatic to the retroperitoneal lymph nodes causing duodenal and small bowel obstruction. Clinical discussion: Squamous cell carcinoma of the bladder, tends to present at later stages and spread to adjacent organs or spread through lymphatics to lymph nodes, liver, bone, brain, lungs, and the gastro-intestinal tract. Diagnosis is made through cystoscopy, pathology and imaging. Non-Bilharzial Squamous cell carcinoma of the bladder is associated with increased morbidity and mortality than its Bilharzial counterpart. Conclusion: This is a unique case of non-bilharzial squamous cell carcinoma of the bladder, metastatic to retroperitoneal lymph nodes that lead to compression of the duodenum and small bowels and eventual gastric outlet obstruction. There are few reports of gastro-intestinal obstruction secondary to bladder cancer, however this is the first case metastatic non-bilharzial Squamous cell carcinoma of the bladder presenting as gastric outlet obstruction. Highlights:
- 1 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 118 (C) , 109625
Open AccessGastric Outlet Obstruction as a presentation of Metastatic Squamous Cell Carcinoma of the Bladder: A case report and review of the literature
Introduction: Gastric outlet obstruction presents with a range of symptoms which include abdominal pain, early satiety, weight loss and vomiting caused obstruction secondary to tumors from outside the gastrointestinal tract or due to motility disorders. Bladder cancer is rarely associated with Gastric outlet obstruction. It usually presents with painless hematuria and urinary symptoms. Squamous cell carcinoma is a subtype of bladder malignancies that tends to present at a later stage and is associated with poorer prognosis in terms of metastasis and survival. Case presentation: We present the case of a 79-year-old man, non-smoker, who presented to the emergency department with gastric outlet obstruction and was found to have non-bilharzial squamous cell carcinoma of the bladder metastatic to the retroperitoneal lymph nodes causing duodenal and small bowel obstruction. Clinical discussion: Squamous cell carcinoma of the bladder, tends to present at later stages and spread to adjacent organs or spread through lymphatics to lymph nodes, liver, bone, brain, lungs, and the gastro-intestinal tract. Diagnosis is made through cystoscopy, pathology and imaging. Non-Bilharzial Squamous cell carcinoma of the bladder is associated with increased morbidity and mortality than its Bilharzial counterpart. Conclusion: This is a unique case of non-bilharzial squamous cell carcinoma of the bladder, metastatic to retroperitoneal lymph nodes that lead to compression of the duodenum and small bowels and eventual gastric outlet obstruction. There are few reports of gastro-intestinal obstruction secondary to bladder cancer, however this is the first case metastatic non-bilharzial Squamous cell carcinoma of the bladder presenting as gastric outlet obstruction. Highlights:
- Open Access
- 1 March 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 116 (C) , 109416
Florid Cystitis Glandularis with Intestinal Metaplasia in the Prostatic Urethra: a case report and review of the literature.
Introduction: Cystitis glandularis is a proliferative disease of the bladder epithelium usually presenting in the setting of chronic inflammation, characterized by the formation of glands in the bladder mucosa and submucosa. Intestinal metaplasia is a described process in cystitis glandularis characterized by the presence of intestinal cells and mucin production which is rare as compared to cystitis glandularis. Case presentation: We present a case of cystitis glandularis with intestinal metaplasia located in the bladder and concomitantly in the prostatic urethra. Patient underwent transurethral resection of the lesion which was unusually found in the prostatic urethra. Clinical discussion: Florid cystitis glandularis is a rare condition found in women more than in men. It usually presents with irritative lower urinary tract symptoms or hematuria which leads to its eventual diagnosis. It is usually causes by inflammation to the bladder mucosa due to infections or irritation. Patients are diagnosed through Transurethral resection of these bladder lesions found in the trigone and bladder neck region. Surgery is the standard treatment of choice. However, medical treatment may also be used to treat underlying inflammatory conditions using antibiotics, steroids, and non-steroidal anti-inflammatory agents. Radical or partial cystectomy may be performed for severe refractory cases. Conclusion: This article describes the rare occurrence of florid cystitis glandularis in the prostatic urethra and provides an overview on diagnosis, etiology, and management of the disease. Highlights:
- 1 March 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 116 (C) , 109416
Open AccessFlorid Cystitis Glandularis with Intestinal Metaplasia in the Prostatic Urethra: a case report and review of the literature.
Introduction: Cystitis glandularis is a proliferative disease of the bladder epithelium usually presenting in the setting of chronic inflammation, characterized by the formation of glands in the bladder mucosa and submucosa. Intestinal metaplasia is a described process in cystitis glandularis characterized by the presence of intestinal cells and mucin production which is rare as compared to cystitis glandularis. Case presentation: We present a case of cystitis glandularis with intestinal metaplasia located in the bladder and concomitantly in the prostatic urethra. Patient underwent transurethral resection of the lesion which was unusually found in the prostatic urethra. Clinical discussion: Florid cystitis glandularis is a rare condition found in women more than in men. It usually presents with irritative lower urinary tract symptoms or hematuria which leads to its eventual diagnosis. It is usually causes by inflammation to the bladder mucosa due to infections or irritation. Patients are diagnosed through Transurethral resection of these bladder lesions found in the trigone and bladder neck region. Surgery is the standard treatment of choice. However, medical treatment may also be used to treat underlying inflammatory conditions using antibiotics, steroids, and non-steroidal anti-inflammatory agents. Radical or partial cystectomy may be performed for severe refractory cases. Conclusion: This article describes the rare occurrence of florid cystitis glandularis in the prostatic urethra and provides an overview on diagnosis, etiology, and management of the disease. Highlights:
- Open Access
- 1 March 2022
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 48 (2) , 98-105
MRI/US fusion transperineal versus transrectral biopsy of prostate cancer: Outcomes and complication rates, a tertiary medical center experience in the Middle East
Objective: To report on the outcomes of transperineal versus transrectal magnetic resonance imaging/ultrasound fusion biopsy of the prostate including detection of clinically significant cancer and complications. This is the first and largest series in the Middle East. Material and methods: Between May 2019 and June 2020, 145 patients with suspicious lesions on magnetic resonance imaging underwent magnetic resonance imaging/ultrasound fusion prostate biopsy at our center. Transperineal biopsy was performed under light sedation, while transrectal biopsy patients had a periprostatic block for anesthesia. Clinically significant cancer was defined as Gleason ≥3+4 Results: In all, 98 transperineal biopsies and 47 transrectal magnetic resonance imaging/ultrasound fusion prostate biopsies were done. Patients had similar prebiopsy parameters (transperineal vs. transrectal): median age (64.5 vs. 66 years; P=.68), median prostate-specific antigen value (7.5 vs. 7.5; P=.42), and median prostate volume (51 vs. 52.5; P=.83). Those that underwent transperineal biopsy had fewer average total number of cores compared to transrectal ultrasound-guided biopsy (11 vs. 13; P=.025) fewer average number of random cores (3 vs. 6; P < .0001), and the detection rate of clinically significant cancer was similar between the groups (44% vs. 48.9%; P=.57). No difference in hematuria, retention, and sepsis rate requiring admission (1 vs. 2; P=.2) was observed. However, more patients had urinary tract infection in the transrectal ultrasound-guided biopsy group compared to transperineal biopsy group (5 vs. 1; P=.006) that were treated with antibiotics on outside basis. Conclusion: Magnetic resonance imaging/ultrasound transperineal fusion biopsy has similar detection rate of clinically significant cancer compared to transrectal ultrasound-guided biopsy with less urinary tract infection post biopsy. Cite this article as: El-Achkar A, Abou Heidar N, Labban M, et al. MRI/US fusion transperineal versus transrectral biopsy of prostate cancer: Outcomes and complication rates, a tertiary medical center experience in the middle east. Turk J Urol. 2022;48(2):98-105.
- 1 March 2022
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 48 (2) , 98-105
Open AccessMRI/US fusion transperineal versus transrectral biopsy of prostate cancer: Outcomes and complication rates, a tertiary medical center experience in the Middle East
Objective: To report on the outcomes of transperineal versus transrectal magnetic resonance imaging/ultrasound fusion biopsy of the prostate including detection of clinically significant cancer and complications. This is the first and largest series in the Middle East. Material and methods: Between May 2019 and June 2020, 145 patients with suspicious lesions on magnetic resonance imaging underwent magnetic resonance imaging/ultrasound fusion prostate biopsy at our center. Transperineal biopsy was performed under light sedation, while transrectal biopsy patients had a periprostatic block for anesthesia. Clinically significant cancer was defined as Gleason ≥3+4 Results: In all, 98 transperineal biopsies and 47 transrectal magnetic resonance imaging/ultrasound fusion prostate biopsies were done. Patients had similar prebiopsy parameters (transperineal vs. transrectal): median age (64.5 vs. 66 years; P=.68), median prostate-specific antigen value (7.5 vs. 7.5; P=.42), and median prostate volume (51 vs. 52.5; P=.83). Those that underwent transperineal biopsy had fewer average total number of cores compared to transrectal ultrasound-guided biopsy (11 vs. 13; P=.025) fewer average number of random cores (3 vs. 6; P < .0001), and the detection rate of clinically significant cancer was similar between the groups (44% vs. 48.9%; P=.57). No difference in hematuria, retention, and sepsis rate requiring admission (1 vs. 2; P=.2) was observed. However, more patients had urinary tract infection in the transrectal ultrasound-guided biopsy group compared to transperineal biopsy group (5 vs. 1; P=.006) that were treated with antibiotics on outside basis. Conclusion: Magnetic resonance imaging/ultrasound transperineal fusion biopsy has similar detection rate of clinically significant cancer compared to transrectal ultrasound-guided biopsy with less urinary tract infection post biopsy. Cite this article as: El-Achkar A, Abou Heidar N, Labban M, et al. MRI/US fusion transperineal versus transrectral biopsy of prostate cancer: Outcomes and complication rates, a tertiary medical center experience in the middle east. Turk J Urol. 2022;48(2):98-105.
- 1 March 2022
- Published by Edizioni Minerva Medica in Minerva Urology and Nephrology
- Vol. 74 (1) , 102-109
Spontaneous ureteral stone passage: a novel and comprehensive nomogram
Article: Spontaneous ureteral stone passage: a novel and comprehensive nomogram - Minerva Urology and Nephrology 2022 February;74(1):102-9 - Minerva Medica - Journals
- 1 March 2022
- Published by Edizioni Minerva Medica in Minerva Urology and Nephrology
- Vol. 74 (1) , 102-109
Spontaneous ureteral stone passage: a novel and comprehensive nomogram
Article: Spontaneous ureteral stone passage: a novel and comprehensive nomogram - Minerva Urology and Nephrology 2022 February;74(1):102-9 - Minerva Medica - Journals